Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement

Abstract Introduction Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, has demonstrated efficacy and safety in phase III trials for moderate-to-severe atopic dermatitis (AD). However, long-term real-world evidence, particularly in European populations and in difficult-to-treat area...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2026-03-01
coleção:	Dermatology and Therapy
Assuntos:	Anti-IL-13 Atopic dermatitis Biologics Lebrikizumab Real-life
Acesso em linha:	https://doi.org/10.1007/s13555-026-01726-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!